Current State of PCR-Based Epstein-Barr Virus DNA Testing for Nasopharyngeal Cancer

Autor: Sue S. Yom, Haja Sittana El Mubarak, Miriam Sander, K.C. Allen Chan, Quynh-Thu Le, Benjamin A. Pinsky, Kelly Y. Kim, Raymond H.W. Ng, Barbara A. Conley, Scott V. Bratman
Rok vydání: 2017
Předmět:
0301 basic medicine
Oncology
Herpesvirus 4
Human
Cancer Research
Medical laboratory
Polymerase Chain Reaction
law.invention
0302 clinical medicine
law
hemic and lymphatic diseases
Viral
Polymerase chain reaction
Cancer
Nasopharyngeal cancer
Tumor
030220 oncology & carcinogenesis
Human
medicine.medical_specialty
Oncology and Carcinogenesis
Biology
Virus
03 medical and health sciences
Rare Diseases
Clinical Research
Internal medicine
Genetics
Biomarkers
Tumor
medicine
Humans
Genetic Testing
Oncology & Carcinogenesis
Dental/Oral and Craniofacial Disease
business.industry
Herpesvirus 4
Epstein-Barr virus DNA
Reproducibility of Results
Nasopharyngeal Neoplasms
DNA
Congresses as Topic
medicine.disease
Virology
Biomarker
030104 developmental biology
Nasopharyngeal carcinoma
DNA
Viral
Commentary
business
Biomarkers
Zdroj: Journal of the National Cancer Institute, vol 109, iss 4
ISSN: 1460-2105
0027-8874
DOI: 10.1093/jnci/djx007
Popis: Clinical studies have shown plasma Epstein-Barr virus (EBV) DNA level to be an independent prognostic biomarker for nasopharyngeal carcinoma (NPC). However, the proportion of NPC patients whose tumors are associated with EBV vary with geographic location, and there are a variety of assays for plasma EBV. To develop the level of evidence needed to demonstrate the clinical utility of plasma EBV DNA detection for NPC patients and encourage widespread adoption of this biomarker test in clinical laboratories, validated harmonized assays are needed. In 2015, the National Cancer Institute (NCI) convened a Workshop on Harmonization of EBV Testing for Nasopharyngeal Cancer, where experts in head and neck oncology and laboratory medicine addressed the limitations of currently available polymerase chain reaction-based EBV DNA quantitation assays and discussed strategies for advancing the development of harmonized EBV DNA assays and their appropriate clinical use. This article presents the key recommendations to direct future efforts in assay harmonization and validation.
Databáze: OpenAIRE
Externí odkaz: